Technical Analysis for INFI - Infinity Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 1.16 -0.85% -0.01
INFI closed down 0.85 percent on Friday, August 23, 2019, on approximately normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical INFI trend table...

Date Alert Name Type % Chg
Boomer Sell Setup Bearish Swing Setup 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Spinning Top Other -0.85%
Wide Bands Range Expansion -0.85%
Oversold Stochastic Weakness -0.85%
Wide Bands Range Expansion 1.75%
Oversold Stochastic Weakness 1.75%
180 Bearish Setup Bearish Swing Setup -2.52%
NR7 Range Contraction -2.52%

Older signals for INFI ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Infinity Pharmaceuticals, Inc., a drug discovery and development company, focuses on discovering, developing, and delivering medicines to patients for diseases with significant unmet need. Its lead product candidates include IPI-145 and IPI-443, inhibitors of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K); Retaspimycin HCl, a heat shock protein 90 inhibitor; and IPI-940, an inhibitor of fatty acid amide hydrolase. The company is pursuing a dual development path for IPI-145 in both hematologic malignancies and inflammation. IPI-145 is in an ongoing Phase I dose-escalation trial in patients with advanced hematologic malignancies and in a Phase IIa study in patients with mild, allergic asthma. In addition, the company plans to initiate a Phase II signal-finding study in patients with rheumatoid arthritis. IPI-443 is undergoing preclinical studies to enable Phase I development. Retaspimycin HCl is in a Phase II trial in combination with docetaxel to treat patients with non-small cell lung cancer (NSCLC) and in an exploratory Phase Ib/II trial in combination with everolimus in NSCLC patients with a KRAS mutation. Infinity Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.
Diseases Chemical Substances Drug Discovery Inflammation Non Small Cell Lung Cancer Rheumatoid Arthritis Hematologic Malignancies Phosphoinositide 3 Kinase Inhibitor Pyrimidines Allergic Asthma Nsclc Purines
Is INFI a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 2.92
52 Week Low 1.0
Average Volume 78,053
200-Day Moving Average 1.5
50-Day Moving Average 1.5229
20-Day Moving Average 1.321
10-Day Moving Average 1.233
Average True Range 0.0876
ADX 36.63
+DI 8.0891
-DI 26.1285
Chandelier Exit (Long, 3 ATRs ) 1.3865
Chandelier Exit (Short, 3 ATRs ) 1.3828
Upper Bollinger Band 1.5684
Lower Bollinger Band 1.0736
Percent B (%b) 0.17
BandWidth 37.456472
MACD Line -0.1068
MACD Signal Line -0.0957
MACD Histogram -0.0112
Fundamentals Value
Market Cap 58.8 Million
Num Shares 50.7 Million
EPS -1.39
Price-to-Earnings (P/E) Ratio -0.83
Price-to-Sales 0.00
Price-to-Book 1.82
PEG Ratio -0.03
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.27
Resistance 3 (R3) 1.27 1.23 1.25
Resistance 2 (R2) 1.23 1.21 1.23 1.24
Resistance 1 (R1) 1.20 1.19 1.18 1.20 1.24
Pivot Point 1.16 1.16 1.16 1.16 1.16
Support 1 (S1) 1.13 1.14 1.11 1.13 1.08
Support 2 (S2) 1.09 1.12 1.09 1.08
Support 3 (S3) 1.06 1.09 1.07
Support 4 (S4) 1.06